Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT041 in Advanced Gastric/GEJ and Pancreatic Cancer
NCT04581473Phase 2Active, not recruiting
- Sponsor
- CARsgen Therapeutics
- Start
- Oct 2020
- Primary completion
- Oct 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of satricabtagene autoleucel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic cancer (PC), sponsored by CARsgen Therapeutics. Started Oct 2020; status: active, not recruiting.
02
Drugs
satricabtagene autoleucel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04581473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581473.